$HEM is currently trading on the TSX-V effortlessly at $0.28 with no such loss percentage recorded yet and is expected to rise significantly in the upcoming week effectively.
$HEM have developed and established a firm market cap which has been on the rise steadily since the listing of the stock on TSX-V, currently the cap valuation is $19.773 Million.
Hemostemix disclosed a non-brokered private offering of about 15 million units to shareholders, priced in the context of the market, with each unit consisting of one common share and one common share purchase warrant.
Hemostemix Inc. announced that it will pay interest of $84,804.40 by issuing 446,339 Common Shares, using the March 2, 2022 closing price of $0.19 per share, to the convertible debenture holder in satisfaction of interest due on the outstanding principal amount of $2,500,000 for the period from inception, June 11, 2021, to December 31, 2021.
After disclosing a secured non-brokered private offering of up to $7.2 million units at $0.14 apiece for gross revenues of roughly $1 million, $HMTXF jumped 3.6 percent on last peek.
$HEM, as the ticker symbol to Hemostemix, listed on TSX-V, is a clinical-stage biotech company and is currently trading for $0.32 with a little fall since the previous closure.
$PQE is a well-performed stock listed on TSX-V. Check out the offering stock price now!
